Evidence map›Paper›PMID 39238110›Full record

Trial reportBJOG : an international journal of obstetrics and gynaecology2025

Preventing Postpartum Venous Thromboembolism With Low-Molecular-Weight Heparin: The PP-HEP Pilot Randomised Controlled Trial.

Marc Blondon, Marine Claver, Emilienne Celetta, Marc Righini, Begoña Martinez de Tejada

2 registry-linked trialsAbstract readPragmatic Clinical TrialRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BJOG : an international journal of obstetrics and gynaecology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04153760 early_phase1completednot on this map

A Pilot Study Assessing the Feasibility of a Randomized Controlled Trial Evaluating Aspirin in Postpartum Women at Risk of Developing Venous Thromboembolism

TypeinterventionalSponsorUniversity of CalgaryRan2020 to 2023Enrolled257ConditionsVenous Thromboembolism, Postpartum Period, AspirinArmsAspirin 81 mg, Placebo
NCT05878899 phase3completednot on this map

Postpartum Heparin Against Venous Thromboembolism: a Pilot Randomized Controlled Trial

TypeinterventionalSponsorUniversity Hospital, GenevaRan2022 to 2023Enrolled77ConditionsVenous ThromboembolismArmsEnoxaparin
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Marc BlondonDivision of Angiology and Hemostasis, Faculty of Medicine, Geneva University Hospitals, Geneva, Switzerland.ORCID https://orcid.org/0000-0001-7032-9491
Marine ClaverDivision of Obstetrics, Department of Paediatrics, Gynecology and Obstetrics, Faculty of Medicine, Geneva University Hospitals, Geneva, Switzerland.
Emilienne CelettaDivision of Obstetrics, Department of Paediatrics, Gynecology and Obstetrics, Faculty of Medicine, Geneva University Hospitals, Geneva, Switzerland.
Marc RighiniDivision of Angiology and Hemostasis, Faculty of Medicine, Geneva University Hospitals, Geneva, Switzerland.
Begoña Martinez de TejadaDivision of Obstetrics, Department of Paediatrics, Gynecology and Obstetrics, Faculty of Medicine, Geneva University Hospitals, Geneva, Switzerland.

Funding

Hôpitaux Universitaires de Genève
6 · The paper itself

Abstract

objectiveUncertainty surrounds the risk-benefit of low-molecular-weight heparin to prevent postpartum venous thromboembolism (VTE). Data from randomised clinical trials (RCT) are critically needed, but recent feasibility studies in North America yielded low participation rates, with <1 enrolment per month per centre. Our aim was to assess the feasibility of a trial of postpartum short-term enoxaparin in Europe.

designPragmatic, open-label pilot randomised controlled trial (RCT).

settingSwiss tertiary hospital. POPULATION: Postpartum women, within 48 h of delivery, deemed at intermediate risk of VTE with at least one major risk factor (morbid obesity, thrombophilia, emergency caesarean section, pre-eclampsia, preterm delivery, intrauterine growth restriction or systemic peripartum infection) and/or at least two minor risk factors.

methodsParticipants were randomised to enoxaparin 40-60 mg once daily for 10 days or no treatment, with a 90-day follow-up.

main outcome measuresParticipation rate and study acceptance (randomised participants among women in whom informed consent was sought).

resultsRecruitment was open for 25 weeks in 2022. Among 1504 postpartum women, 480 were eligible and 77 were randomised. The recruitment rate was 3.1 per week (13.3 per month) and the study acceptance was 23.8%. At 3 months, there was no VTE event, but one major, one nonmajor obstetrical bleeding and one surgical site complication, all in the enoxaparin group.

conclusionsThis pilot RCT of postpartum thromboprophylaxis set in Switzerland yielded greater participation rate and acceptance than previous attempts in North America. It calls for a large, international, collaborative trial to guide this important clinical decision.

trial registrationClinicalTrial.gov identifier: NCT05878899 and NCT04153760.

Indexed as

AnticoagulantsEnoxaparinVenous ThromboembolismAdultFeasibility StudiesFemaleHeparin, Low-Molecular-WeightHumansPilot ProjectsPostpartum PeriodPregnancyPuerperal DisordersRisk FactorsSwitzerlandTreatment OutcomeAnticoagulantsEnoxaparinHeparin, Low-Molecular-Weightlow‐molecular‐weight heparinpostpartumpregnancyvenous thrombosis

Identifiers

PMID39238110
PMCPMC11612613

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.